Bile Acids in Acute Insulin Resistance

Bile Acids in Acute Insulin Resistance
Patients treated with PI3K/AKT/mTOR inhibitors for cancer

Patients with cancer being treated pwith PI3K/AKT/mTOR inhibitors will be studied prospectively for the impact of treatment on bile acid metabolism as a function of drug-induced acute insulin resistance. Treatments will be selected by patients’ treating oncologist based on standard of care.

Drug: Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor

Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 8, 2022Comments | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine